We develop alternatives to antibiotics to replace ineffective or restricted drugs on the market.
We have identified and validated the poultry sector as an early revenue generator and a valuable testbed for human drugs.
Within four years, we aim to reach our beachhead market of poultry production in Canada. We will then quickly expand to the US and beyond.
As our assets successfully emerge, they will be out-licensed to biopharma companies.